BY MIKKEL AABENHUS HEMMINGSEN
-
Phase III results send multi-blockbuster closer to another indication
Based upon the outcomes of the research study, Sanofi and Regeneron will certainly start the procedure of obtaining Dupixent accepted in the United States later on this year.
-
Job change leads to board reshuffle at Demant
The head of team conformity is leaving the listening devices company.
-
Report: Biopharma sector had strongest investment quarter in two years
There was additionally less departures throughout the duration.
-
Lundbeck tests its “most promising” potential migraine candidate in Ph1 combination trial
40 individuals are to be hired for the test.
-
Ambu CFO on recent success: We now have money for acquisitions
The buying power presently totals up to DKK 2.5 bn.
-
Wegovy reduced Covid deaths in obese patients, study shows
The searchings for were released Friday in the Journal of the American University of Cardiology.
-
FDA approves insulin pump for new patient group
The modern technology changes insulin application by linking an insulin pump with an incorporated sugar meter.
-
Amgen launches tablet for children with psoriasis in the US
Otezla’s income in 2023 was USD 2.2 bn.
-
Singapore approves smallpox vaccine from Bavarian Nordic
The vaccination has actually formerly been provided an emergency situation usage license in the nation.
-
What Is TVBoost And Does It Really Work?
TVBoost antennas make a great deal of insurance claims regarding their capacities and regarding what over-the-air programs can. Is it worth purchasing one …Read More
